Skip to content

Population pharmacokinetic and pharmacodynamicspmodel study of clozapine in refractory schizophrenia patients

Population pharmacokinetic and pharmacodynamicspmodel study of clozapine in refractory schizophrenia patients

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-TNC-10000840
Enrollment
Unknown
Registered
2007-03-15
Start date
2008-08-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pyschosis

Interventions

1:treatment with clozapine

Sponsors

Beijing Anding Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria were: 1. Patients met ICD-10 for schizophrenia; 2. PANSS>=60; 3. failed trials of at least 8 weeks on what should have been a therapeutic dose of at least 3 conventional antipsychotics of 2 different classes; 4. age >=18, male or female; 5. to be able to and willingness to fulfil the stuty; 6. All patients or their caregivers were informed, and gave consent to take part in the study.

Exclusion criteria

Exclusion criteria: Exclusion criteria were: 1. current or past history of serious medical illness, for example renal diseases, liver diseases, epilepsy, severely cardiovascular diseases, endocrine system diseases, CNS Diseases, particularly blood dyscrasia and bone marrow disorder; 2. have received the treatment of ECT in the past month; 3. history of alcohol or drug abuse; 4. pregnancy or lactation; 5. a diagnosis other than schizophrenia (include comorbidity); 6. other fators that the investor don't think fit to including.

Design outcomes

Primary

MeasureTime frame
PANSS;Clozapine blood concentratio;

Countries

China

Contacts

Public ContactChuanyue Wang
wang.cy@163.net+86 010 58303195

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026